Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Vicarious Surgical’s SEC paperwork often means decoding pages of robotics engineering details, FDA trial data, and prototype cost breakdowns. If you have ever searched for “Vicarious Surgical SEC filings explained simply” or wondered how executive stock sales line up with regulatory milestones, you know the challenge.
Stock Titan solves that complexity. Our AI instantly scans every new document from the company’s real-time EDGAR feed—whether it’s a Vicarious Surgical quarterly earnings report 10-Q filing or a sudden Vicarious Surgical 8-K material events explained alert—and delivers plain-language summaries, trend charts, and red-flag highlights. You will see cash-burn trends, R&D outlays, and single-port robotics development updates without wading through technical jargon.
Here is what investors monitor most—and how our platform helps:
- 10-K / Annual insight: Get the Vicarious Surgical annual report 10-K simplified so you can track FDA pathway progress and component sourcing risks.
- 10-Q / Quarterly performance: Compare revenue runway and prototype expenses with our Vicarious Surgical earnings report filing analysis.
- Form 4 insider alerts: Follow Vicarious Surgical insider trading Form 4 transactions and receive Vicarious Surgical Form 4 insider transactions real-time push notices.
- Proxy statement: Drill into Vicarious Surgical proxy statement executive compensation to see how bonuses hinge on FDA milestones.
Need deeper context? Try understanding Vicarious Surgical SEC documents with AI—our narrative commentary ties robotic-arm dexterity claims to actual spending, while clear call-outs show Vicarious Surgical executive stock transactions Form 4 right next to board meeting dates. From early-morning 8-K announcements to late-day amendment filings, every disclosure appears on this page within minutes, already distilled into the insights that matter.
Vicarious Surgical Inc. director and executive reports small share sale. A reporting person who is a director, 10% owner, and Chief Technology Officer of Vicarious Surgical Inc. (RBOT) reported selling 653 shares of Class A common stock on 11/20/2025 at a weighted average price of $2.744 per share. After this transaction, the reporting person beneficially owned 33,862 shares directly.
The company explains that the sale was carried out under its equity incentive plan to cover tax withholding obligations arising from the vesting of restricted stock units granted on May 19, 2022, and that it was a mandated "sell to cover" transaction rather than a discretionary trade.
Vicarious Surgical Inc. (RBOT) reported an insider transaction by a reporting person who is a director, president, and 10% owner. On 11/20/2025, the insider sold 816 shares of Class A common stock in a transaction coded “S”. The weighted average sale price was $2.715 per share, with individual trade prices ranging from $2.54 to $2.94 per share.
The filing explains that the sale was executed solely to cover tax withholding obligations arising from the vesting of restricted stock units granted on May 19, 2022, under the company’s equity incentive plan, and was not a discretionary trade. After this transaction, the insider beneficially owned 48,348 shares of Class A common stock.
Vicarious Surgical Inc. (RBOT)
The notice also reports prior sales by the same seller over the past three months: 653 shares sold on 08/20/2025 for gross proceeds of 3,801 and 239 shares sold on 09/03/2025 for gross proceeds of 1,293. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about Vicarious Surgical’s current or prospective operations.
Vicarious Surgical Inc. (RBOT)
The filing also lists sales by the same seller during the prior three months, including 817 shares sold on 08/20/2025 and 463 shares sold on 09/03/2025. By signing the notice, the seller represents that he is not aware of any material adverse, nonpublic information about the company’s current or future operations.
Vicarious Surgical Inc. filed a Form S-3 to register the resale of up to 2,300,000 shares of Class A common stock. These shares are issuable upon exercise of Series A and Series B common warrants previously sold in an October 2025 private placement.
The company is not selling any shares in this registration and will receive no proceeds from resales; it would receive cash only if holders exercise warrants, which have a $5.10 exercise price and become exercisable upon required stockholder approval. Beneficial ownership caps limit exercises to 4.99% (or 9.99% if elected). Shares outstanding were 5,894,273 as of November 12, 2025. RBOT last traded at $4.57 on November 11, 2025.
Vicarious Surgical (RBOT) filed its Q3 2025 10‑Q and flagged liquidity risk. The company reported a Q3 net loss of
Cash, cash equivalents and short‑term investments were
The company remains pre‑revenue and continues R&D on its single‑port surgical robot, noting controlled builds in
Vicarious Surgical Inc. furnished an 8‑K announcing its results for the third quarter ended September 30, 2025, along with a business update. The company provided the details via a press release furnished as Exhibit 99.1.
The company noted that the information in this report, including Exhibit 99.1, is being furnished and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference unless expressly stated.
Vicarious Surgical Inc. (RBOT) filed a Form D reporting a private placement under Rule 506(b)Total Amount Sold of $11,730,000 and Total Remaining $0. The filing notes the total offering amount reflects gross proceeds assuming cash exercise of all warrants issued in the private placement.
The securities include equity, warrants or other rights to acquire securities, and securities to be acquired upon exercise. The Date of First Sale was 2025-10-09. Lake Street Capital Markets, LLC acted as placement agent, receiving a 6.0% cash fee on gross proceeds plus $100,000 expense reimbursement.
The company indicates proceeds are for working capital; while none are specifically set aside for officers or directors, some working capital may indirectly cover executive salaries and director stipends. Industry is listed as Health Care — Biotechnology, and issuer size was marked “Decline to Disclose.”
Vicarious Surgical Inc. is offering Class A common stock at
Reported per-share net tangible book value before the offering is
Risk disclosures highlight barriers in the surgical robotics market: legacy systems have limited capabilities, are difficult to use, show low utilization, and carry significant capital investment costs—estimated up to
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
